T he Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, involving 9,795 patients with type 2 diabetes, is the largest study to date investigating the role of a lipid-modifying therapy in reducing cardiovascular risk in type 2 diabetes. Although the reduction in the primary end point (non-fatal myocardial infarction [MI] and coronary heart disease [CHD] death) did not reach statistical significance, fenofibrate treatment was associated with a significant reduction in total cardiovascular events, largely driven by reductions in non-fatal MI and revascularisation procedures.
Introduction
Patients with type 2 diabetes commonly present with an atherogenic dyslipidaemia characterised by an increase in triglycerides, a decrease in plasma levels of high-density lipoprotein cholesterol (HDL-C), as well as increased prevalence of small, dense low-density lipoprotein (LDL) particles (collectively termed the 'lipid triad'). This atherogenic dyslipidaemic profile contributes to markedly increased cardiovascular risk in this patient group. [1] [2] [3] Given the pharmacological profile of the fibrates, 4 it can be anticipated that these agents could provide specific vascular protection in patients with type 2 diabetes by normalising their lipid profile, raising HDL-C, decreasing triglyceride levels and shifting LDL particle size towards more buoyant, larger and less atherogenic LDL. 4, 5 Promising data from the Veterans Affairs HDL Intervention Trial (VA-HIT) 6 showed a greater reduction in the composite end point of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI) and stroke in patients with diabetes compared to those without diabetes treated with the fibrate gemfibrozil (32% vs. 18%). In addition, the Diabetes Atherosclerosis Intervention Study (DAIS) demonstrated significantly less angiographic progression of coronary stenosis in patients with diabetes who were treated with fenofibrate. 7 Together, these data provided the rationale for a major prospective outcome study to evaluate fully the potential clinical benefits of fibrate therapy in reducing cardiovascular risk in patients with type 2 diabetes.
FIELD: effect on macrovascular disease
The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a landmark study designed to investigate the efficacy and tolerability of fenofibrate treatment in patients with type 2 diabetes with and without established cardiovascular disease. In total, 9,795 patients with type 2 diabetes were enrolled and, following a 16-week run-in period comprising four weeks of dietary modification, six weeks of single-blind placebo and six weeks of singleblind fenofibrate therapy, they were randomised to treatment with fenofibrate 200 mg/day (n=4,895) or placebo (n=4,900). 8 All patients had a total cholesterol of between 3.0 and 6.5 mmol/L plus either a total cholesterol/HDL-C ratio > 4.0 or plasma triglycerides of 1.0-5.0 mmol/L, and had no clear indication for and were not on treatment with lipid-modifying therapy. The baseline characteristics of the two groups were similar. The majority of patients were borderline obese (median body mass index 29.8 kg/m 2 ) and 38% had the characteristic dyslipidaemia associated with type 2 diabetes (i.e. elevated triglycerides and low HDL-C levels). Most patients (78%) did not have clinical evidence of prior cardiovascular disease. 8 Of note, patients were at a relatively early stage of diabetes (median duration of disease five years), as evident by a relatively low incidence of microvascular disease (21% in the fenofibrate group and 20% in the placebo group), and they had optimal glycaemic control (HbA 1C 6.9%) which was maintained over the course of the study (table 1) . 8 At the end of the five-year follow-up period, treatment with fenofibrate was associated with an 11% reduction in the relative risk of the primary end point (non-fatal MI and CHD death), although this did not reach statistical significance (p=0.16). There was a statistically significant 11% reduction in the secondary end point of total cardiovascular events (p=0.035) (figure 1), largely driven by significant reductions in non-fatal MI (by 24%, p=0.01) and the need for coronary and all revascularisation procedures (by 21%, p=0.003 and 20%, p=0.001, respectively) (table 2).
Subgroup analyses showed that fenofibrate was more effective in the primary prevention setting. In these patients, there was a significant relative risk reduction in total cardiovascular events of 19% (p=0.004), compared with no effect in patients with prior cardiovascular disease (25.5% of the fenofibrate group compared with 25.1% of the placebo group had events). In addition, post-hoc analysis showed a significant proportional reduction in major coronary events in patients without prior cardiovascular disease (by 25%, p=0.014), compared with a non-significant 8% increase in patients with prior cardiovascular disease. 8 Key studies reported after the initiation of FIELD, most notably the Heart Protection Study (HPS), 9 demonstrated the benefit of statin therapy in patients with diabetes with, or at risk for, cardiovascular disease. Not unexpectedly, in FIELD a relatively high drop-in rate of lipid-modifying therapy (predominantly statins) was observed in both treatment groups; it was higher in the placebo group (36% vs. 19% at study close-out). 8 This had been anticipated by the investigators, who performed an adjusted analysis of the study data, taking into account the excess of statin use in the placebo arm. Non-significant increases in total and cardiac mortality of 11% and 19%, respectively, were observed in the fenofibrate group in the main analysis. 8 Given that the use of other treatments for cardiovascular disease was similar in each group, it is possible that the non-significant increase in total and cardiac mortality in the fenofibrate group might be accounted for partly by the excess statin use in the placebo group, which may have reduced CHD mortality to a larger extent than in the fenofibrate group.
Why did the results of FIELD differ from those observed in major statin studies?
The magnitude of the reduction in cardiovascular events in patients with diabetes that was observed in FIELD 8 was lower than that observed in major statin studies such as the HPS 9 and the Collaborative Atorvastatin Diabetes Study (CARDS) 10 (11% vs. 22% and 37%, respectively) although similar with 11 However, it should be noted that in ASPEN an extended primary composite end point was used, which comprised cardiovascular death, nonfatal MI, non-fatal stroke, recanalisation, coronary artery bypass surgery, resuscitated cardiac arrest, and worsening or unstable angina requiring hospitalisation. 11 Inclusion of hospitalisation for angina and recanalisation may have diluted the treatment effect with atorvastatin, contributing to the lack of statistical significance observed in this study. As previously discussed, the lack of a statistically significant reduction in the primary end point with fenofibrate in FIELD may be partly attributed to disproportionately higher drop-in statin use in the placebo compared to the active treatment group. 8 This effect was also observed in ASPEN, as the Data Safety Monitoring Board recommended replacement of the study treatment with usual care for all patients with an adjudicated study end point (33% of atorvastatin-treated patients and 42% of the placebo patients). Thus, 26.9% of the placebo group compared with 15.4% of the atorvastatin group received concomitant lipid-lowering treatment. 11 In addition, differences in the characteristics of the patient population between the studies, (which in turn influence the level of cardiovascular risk) may account for the observed differences. Insulin resistance, dyslipidaemia and hypertension all contribute to increased cardiovascular risk, which is apparent even before the onset of glucose intolerance. 12 Thus, the duration of diabetes influences the associated cardiovascular risk. In FIELD, patients had diabetes at a relatively early stage (median duration of disease was five years), 8 compared with a duration of diabetes of eight years (in CARDS 10 and ASPEN 11 ) and nine years in the HPS. 9 Glycaemic control was optimal in the FIELD study, with median HbA 1C levels 6.9% at entry and 7.0% at study close in the fenofibrate group and 6.9% at entry and study close in the placebo group. 8 In contrast, baseline glycaemic control in the CARDS population was less than satisfactory (7.8%), and deteriorated further during the course of the four-year follow-up period (8.3% in the atorvastatin group and 8.1% in the placebo group). 10 Evidence from the United Kingdom Prospective Diabetes Study (UKPDS) indicates that increasing HbA 1C by 1% above a value of 7% increases cardiovascular risk by 14%. 13 Subgroup analyses of previous statin studies 14, 15 have demonstrated that low plasma levels of HDL-C can influence coronary risk. Therefore, raising HDL-C in patients with suboptimal levels may provide additional benefit. In FIELD, although there was a suggestion of greater cardiovascular benefit in the subgroup with low HDL-C (< 1.03 mmol/L [40 mg/dL] in men and < 1.29 mmol/L [50 mg/dL] in women) at baseline, the interaction test between treatment effect and low/high HDL subgroups was not statistically significant (p=0.3). 8 Taking all of these characteristics into account, it is evident that the FIELD population had a substantially lower cardiovascular risk at baseline than that in either the CARDS or HPS populations and was even slightly lower than the ASPEN population (table 1). Using the Framingham risk score, 5 the 10-year risk of a coronary event was estimated at 12% for the FIELD population, compared with 20-25% for CARDS and 25-72% for the HPS populations. It is also noteworthy that, of patients enrolled in FIELD, only 38% had the atherogenic dyslipidaemic profile characteristic of type 2 diabetes (i.e. elevated triglycerides and low HDL-C). 8 Therefore it is likely that fenofibrate would have been less effective in the FIELD patient population than in those who predominantly had the atherogenic dyslipidaemia of type 2 diabetes, as in the CARDS and the HPS populations. 9,10 REVIEW Preferential benefit in the primary prevention setting Most patients in FIELD (78%) 8 and ASPEN (79%) 11 and all patients in CARDS 10 did not have prior clinical evidence of cardiovascular disease; in the HPS, 9 50% of patients had established cardiovascular disease at entry (table 1) . Pre-specified subgroup analysis of the FIELD database showed a greater reduction in total cardiovascular events with fenofibrate in patients without prior cardiovascular disease (risk reduction 19%, p=0.004) compared with no effect in those patients with established cardiovascular disease. 8 In addition, post-hoc analysis showed significant reduction in the primary study end point in the primary prevention setting (by 25%, p=0.014) compared with a nonsignificant 8% increase in patients with established cardiovascular disease. 8 These data suggest that patients with type 2 diabetes and established cardiovascular disease may be less responsive to the effects of lipid-modifying treatment, and therefore more difficult to treat.
Data from the HPS support this hypothesis. In this study, simvastatin treatment in patients who had diabetes but no prior cardiovascular disease was associated with a greater proportional reduction in the risk of first major vascular events over five years than that observed among patients with both diabetes and established cardiovascular disease (32.9% vs. 18.4%). 9 This is also supported by CARDS, which demonstrated a significant 37% proportional reduction in cardiovascular disease events associated with atorvastatin treatment in the primary prevention setting. 10 In contrast, findings from ASPEN 11 differed from the majority of statin studies including the HPS 9 and CARDS. 10 Although not statistically significant, the treatment effect observed with atorvastatin 10 mg/day in ASPEN appeared to be greater in the subgroup of patients with prior MI or interventional procedures than in those without (relative risk reduction 18% vs. 3%, respectively).
FIELD: promising effects on microvascular disease
FIELD is the first major study involving lipid-modifying therapy to have shown promising effects on the microvascular complications associated with type 2 diabetes. Treatment with fenofibrate, compared with placebo, was associated with significant reduction in the need for retinal laser therapy (p=0.0003) ( figure 2) . Data on the effect of fenofibrate on albumin excretion rate, 8 although promising, are still under investigation by the FIELD Scientific Committee. If confirmed, these latter findings may corroborate preliminary evidence from DAIS, 16 which demonstrated attenuation of the progression of albuminuria in patients with type 2 diabetes who were treated with fenofibrate. There were other potential benefits of fenofibrate on the microvasculature, specifically a reduction in the number of patients undergoing leg amputation compared with placebo (51 vs. 74 events, relative risk reduction 31%, p=0.04). 17 Findings from the UKPDS 18 had previously shown that the development of microvascular complications of type 2 diabetes is largely dependent on glycaemic control (figure 3). In this study, intensive glycaemic control reduced the risk of retinopathy and albuminuria over a 12-year period by 21% and 33%, respectively. 18 As previously discussed, the FIELD patient population was notable for optimal glycaemic control, which was maintained throughout the study. The changes in concomitant cardiovascular medication (other than lipid-modifying therapy) observed in FIELD were similar in the active and placebo treatment groups. 8 Even though there was a slightly greater blood pressure reduction in the fenofibrate group than the placebo group at the end of the study (median reduction 4/5 mmHg vs. 2/4 mmHg), it is unlikely that this effect explains the promising effect of fenofibrate on diabetes-related microvascular complications. 8 Thus, as postulated by Chapman 19 in this supplement, it is likely that the promising microvascular effects associated with fenofibrate in FIELD can be explained on the basis of a direct effect of fenofibrate on endothelial dysfunction and inflammation, which are important mediators of the microvascular effects of prolonged hyperglycaemia in target tissues such as in the REVIEW Figure 2 . In FIELD, treatment with fenofibrate was associated with a significant reduction in the need for retinal laser therapy 7 10 kidney and eye. 20 Certainly further investigation of these effects is warranted.
FIELD: fenofibrate was well tolerated FIELD confirmed the good tolerability of fenofibrate, either alone or in combination with a statin, in patients with diabetes. Not only were drop-out rates comparable in the fenofibrate and placebo treatment arms (11% vs. 10%), but there was also a similar incidence of serious adverse events considered possibly related to the study treatment in each group (0.8% and 0.5%). 8 Compared with the placebo group, there were slight increases in the risk of pancreatitis and pulmonary embolism in patients receiving fenofibrate (0.8% vs. 0.5%, p=0.031; 1.1% vs. 0.7%, p=0.022). The possible pathophysiological link(s) accounting for the slight increase in deep vein thrombosis and pulmonary embolism is currently under study by the FIELD Investigators, and a clear explanation has yet to be found. However, there were no significant increases in liver enzymes, creatine phosphokinase, newly diagnosed cancer, myositis, rhabdomyolysis or renal disease in patients treated with fenofibrate, either alone or in combination with a statin. 8 There were very few cases of muscle toxicity reported during the study (three patients in the fenofibrate group and one in the placebo group developed rhabdomyolysis: two patients and one patient, respectively, developed myositis). In this study no patient on a combination of fenofibrate plus a statin developed myopathy or rhabdomyolysis. 8 Although there were small increases in plasma levels of homocysteine and creatinine in the fenofibrate group at study close, these were reversible following discontinuation of therapy. 8 Synopsis FIELD was a landmark study which provided important evidence of the benefits of fenofibrate treatment in attenuating microvascular and macrovascular complications in patients with type 2 diabetes. 8 Differences in the magnitude of the reduction in cardiovascular risk in FIELD 8 compared with data from the populations of patients with diabetes in the HPS, 9 CARDS 10 and ASPEN 11 emphasise the importance of considering differences in patient characteristics, which impact on the overall level of cardiovascular risk. Taking into account such differences, the FIELD data indicate that fenofibrate is a suitable, well-tolerated treatment (alone or most likely in combination with a statin) in patients with early-stage type 2 diabetes without evidence of cardiovascular disease, to reduce the residual risk of cardiovascular disease that exists even in the presence of statin therapy. Data are awaited from the ongoing Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial to confirm the outcome benefits of combination fibrate/statin therapy in patients with type 2 diabetes. Finally, the effects of fenofibrate on attenuating the microangiographic manifestations of diabetes observed in FIELD 8 are interesting, and warrant investigation in other studies
